Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Jitske van den Bulk (17142147) (author)
Άλλοι συγγραφείς:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Έκδοση:	2025
Θέματα:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
ανά: Jitske van den Bulk (17142147)
Έκδοση: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
ανά: Jitske van den Bulk (17142147)
Έκδοση: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
ανά: Jitske van den Bulk (17142147)
Έκδοση: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
ανά: Jitske van den Bulk (17142147)
Έκδοση: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
ανά: Maria Lozano-Rabella (15056515)
Έκδοση: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
ανά: Maria Lozano-Rabella (15056515)
Έκδοση: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
ανά: Maria Lozano-Rabella (15056515)
Έκδοση: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
ανά: Caroline Robert (15032672)
Έκδοση: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
ανά: Caroline Robert (15032672)
Έκδοση: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
ανά: Caroline Robert (15032672)
Έκδοση: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
ανά: Caroline Robert (15032672)
Έκδοση: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
ανά: Hansol Lee (15054787)
Έκδοση: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
ανά: Hansol Lee (15054787)
Έκδοση: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
ανά: Hansol Lee (15054787)
Έκδοση: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
ανά: Hansol Lee (15054787)
Έκδοση: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
ανά: Ankita Mitra (17141783)
Έκδοση: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
ανά: Ankita Mitra (17141783)
Έκδοση: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
ανά: Ankita Mitra (17141783)
Έκδοση: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
ανά: Wei Liu (20030)
Έκδοση: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
ανά: Christine Pich-Bavastro (16509238)
Έκδοση: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
ανά: Rohit Thummalapalli (17314483)
Έκδοση: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
ανά: Wei Liu (20030)
Έκδοση: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
ανά: Wei Liu (20030)
Έκδοση: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
ανά: Wei Liu (20030)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_he8fdprohtm0e49l2jqr4g1s1b